Antíxeno prostático específico (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Antíxeno prostático específico" in Galician language version.

refsWebsite

Global rank Galician rank

12nih.gov

4^th place

6^th place

6web.archive.org

1^st place

3archive.org

6^th place

8^th place

3worldcat.org

5^th place

11^th place

1cancer.gov

1,684^th place

1,367^th place

1jco.org

low place

1andrologysociety.com

low place

1nytimes.com

7^th place

32^nd place

1cancer.org

3,680^th place

3,865^th place

1proscar.com

low place

1merck.com

6,464^th place

8,835^th place

1medscape.com

719^th place

690^th place

1oxfordjournals.org

1,389^th place

239^th place

1doi.org

2^nd place

7^th place

1scielo.org.ve

low place

7,371^st place

1jhu.edu

699^th place

519^th place

1asco.org

low place

andrologysociety.com

"Chapter 8: What is the prostate and what is its function?". American Society of Andrology Handbook. Arquivado dende o orixinal o 12 de xaneiro de 2010. Consultado o 17 de setembro de 2006.

archive.org

Mytrle, J. F., Ivor, L. (1989). "Measurement of Prostate-Specific Antigen (PSA) in Serum by a Two-Site Immunometric Method (Hybritech Tandem®-R/Tandem®-E PSA)". Clinical Aspects of Prostate Cancer. Assessment of New Diagnostic and Management Procedures. Proceedings of a workshop of the Prostate Cancer Working Group of the National Cancer Institute's Organ Systems Program, held October 16-19, 1988 at Prout's Neck, Maine, U.S.A. Nova York: Elsevier. pp. 161-71. ISBN 0-444-01514-0.
Mytrle, J. F. (1989). "Normal Levels of Prostate-Specific Antigen (PSA)". Clinical Aspects of Prostate Cancer. Assessment of New Diagnostic and Management Procedures. Proceedings of a workshop of the Prostate Cancer Working Group of the National Cancer Institute's Organ Systems Program, held October 16-19, 1988 at Prout's Neck, Maine, U.S.A. Nova York: Elsevier. pp. 183-9. ISBN 0-444-01514-0.
Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, Minasian L, Ford L, Lippman S, Crawford E, Crowley J, Coltman C (2004). "Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.". N Engl J Med 350 (22): 2239–46. PMID 15163773.

asco.org

ASCO.org, sitio web da American Society of Clinical Oncology (Sociedade Estadounidense de Oncoloxía Clínica), en inglés.

cancer.gov

«Análisis del antígeno prostático específico (PSA)». National Cancer Institute, NCI. Consultado o 11 de marzo de 2014.

cancer.org

American Cancer Society (26 de xullo de 2006). "Can Prostate Cancer Be Found Early?". Detailed Guide: Prostate Cancer. Arquivado dende o orixinal o 01 de setembro de 2006. Consultado o 14 de setembro de 2006.

doi.org

dx.doi.org

Chuang AY, Demarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007). "Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma" 31 (8): 1246–1255. PMID 17667550. doi:10.1097/PAS.0b013e31802f5d33.

jco.org

Balk, Steven P.; Yoo-Joung Ko, Glenn J. Bubley (2003). "Biology of Prostate-Specific Antigen". Journal of Clinical Oncology 28 (2): 383–91. Arquivado dende o orixinal (Abstract) o 25 de setembro de 2006. Consultado o 17 de setembro de 2006.

jhu.edu

urology.jhu.edu

Tablas de Partin^{[Ligazón morta]}

medscape.com

Medscape - Prostate Cancer Resource Center. "Copia archivada". Arquivado dende o orixinal o 2 de febreiro de 2009. Consultado o 12 de outubro de 2007.

merck.com

Propecia

nih.gov

ncbi.nlm.nih.gov

Lilja, H. (novembro de 2003). "Biology of Prostate-Specific Antigen". Urology 62 ((5 Suppl 1)): 27–33. PMID 14607215. |data-acceso= require |url= (Axuda)
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman S. M., Crawford, E. D., Crowley, J. J., Coltman Jr., C. A. (27 de maio de 2004). "Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter". N Engl J Med 350 (22): 2239–46. PMID 15163773.
Carter HB (27 de maio de 2004). "Prostate cancers in men with low PSA levels--must we find them?". N Engl J Med 350 (22): 2292–4. PMID 15163780.
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (25 de abril de 1991). "Measurement of prostate-specific antigen in serum as a screening test for prostate cancer". N Engl J Med 324 (17): 1156–61. PMID 1707140.
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., De Kernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L.; et al. (maio de 1994). "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men". J Urol 151 (5): 1283–90. PMID 7512659.
Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J, deKernion J, Walsh P, Scardino P, Lange P, Subong E, Parson R, Gasior G, Loveland K, Southwick P (1998). "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.". JAMA 279 (19): 1542–7. PMID 9605898.
Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, Minasian L, Ford L, Lippman S, Crawford E, Crowley J, Coltman C (2004). "Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.". N Engl J Med 350 (22): 2239–46. PMID 15163773.
Herschman JD, Smith DS, Catalona WJ (1997). "Effect of ejaculation on serum total and free prostate-specific antigen concentrations". 50 (2). pp. 239–43.
Catalona W, Smith D, Ornstein D (1997). "Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.". JAMA 277 (18): 1452–5. PMID 9145717.
Carter H, Pearson J, Metter E, Brant L, Chan D, Andres R, Fozard J, Walsh P (1992). "Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.". JAMA 267 (16): 2215–20. PMID 1372942.
D'Amico A, Chen M, Roehl K, Catalona W (2004). "Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.". N Engl J Med 351 (2): 125–35. PMID 15247353.
Chuang AY, Demarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007). "Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma" 31 (8): 1246–1255. PMID 17667550. doi:10.1097/PAS.0b013e31802f5d33.

nytimes.com

query.nytimes.com

Kolota, Gina (30 de maio de 2004). "It Was Medical Gospel, but It Wasn't True". The New York Times: p. 4.7.

oxfordjournals.org

jncicancerspectrum.oxfordjournals.org

H. Ballentine Carter (2006). "Assessing Risk: Does This Patient Have Prostate Cancer?". Journal of the National Cancer Institute 98 (8): 506–7. Arquivado dende o orixinal (Editorial) o 19 de xullo de 2006. Consultado o 14 de setembro de 2006.

proscar.com

Proscar

scielo.org.ve

www2.scielo.org.ve

Sempere, Pilar. Evolución del tratamiento con radioterapia convencional del cáncer de próstata desde 1984 hasta el 2000. Rev. venez. oncol. [en liña]. xullo de 2005, vol. 17, no. 3 [citado o 12 de outubro de 2007], 141-147. Dispoñible en: "Copia archivada". Arquivado dende o orixinal o 31 de xaneiro de 2009. Consultado o 13 de outubro de 2007. . ISSN 0798-0582.

web.archive.org

Balk, Steven P.; Yoo-Joung Ko, Glenn J. Bubley (2003). "Biology of Prostate-Specific Antigen". Journal of Clinical Oncology 28 (2): 383–91. Arquivado dende o orixinal (Abstract) o 25 de setembro de 2006. Consultado o 17 de setembro de 2006.
"Chapter 8: What is the prostate and what is its function?". American Society of Andrology Handbook. Arquivado dende o orixinal o 12 de xaneiro de 2010. Consultado o 17 de setembro de 2006.
American Cancer Society (26 de xullo de 2006). "Can Prostate Cancer Be Found Early?". Detailed Guide: Prostate Cancer. Arquivado dende o orixinal o 01 de setembro de 2006. Consultado o 14 de setembro de 2006.
Medscape - Prostate Cancer Resource Center. "Copia archivada". Arquivado dende o orixinal o 2 de febreiro de 2009. Consultado o 12 de outubro de 2007.
H. Ballentine Carter (2006). "Assessing Risk: Does This Patient Have Prostate Cancer?". Journal of the National Cancer Institute 98 (8): 506–7. Arquivado dende o orixinal (Editorial) o 19 de xullo de 2006. Consultado o 14 de setembro de 2006.
Sempere, Pilar. Evolución del tratamiento con radioterapia convencional del cáncer de próstata desde 1984 hasta el 2000. Rev. venez. oncol. [en liña]. xullo de 2005, vol. 17, no. 3 [citado o 12 de outubro de 2007], 141-147. Dispoñible en: "Copia archivada". Arquivado dende o orixinal o 31 de xaneiro de 2009. Consultado o 13 de outubro de 2007. . ISSN 0798-0582.

worldcat.org

Sempere, Pilar. Evolución del tratamiento con radioterapia convencional del cáncer de próstata desde 1984 hasta el 2000. Rev. venez. oncol. [en liña]. xullo de 2005, vol. 17, no. 3 [citado o 12 de outubro de 2007], 141-147. Dispoñible en: "Copia archivada". Arquivado dende o orixinal o 31 de xaneiro de 2009. Consultado o 13 de outubro de 2007. . ISSN 0798-0582.
Grupo de Expertos en Cáncer de Próstata. Cáncer de próstata de alto riesgo y diseminado (Documento de Consenso de Recomendaciones). Actas Urol Esp. [en liña]. 2005, vol. 29, no. 9 [citado 13-10-2007], 826-827. Dispoñible en: . ISSN 0210-4806.
Castelo Elías-Calles, L. e Machado Porro, M. C. Algunas consideraciones sobre el síndrome de PADAM. Rev Cubana Endocrinol. [en liña]. maio-agosto 2006, vol.17, no.2 [citado o 12 de outubro de 2007], p.0-0. Dispoñible en: . ISSN 1561-2953.